Mark M Schubert

Summary

Affiliation: Seattle Cancer Care Alliance
Country: USA

Publications

  1. ncbi request reprint The 20 item oral mucositis index: reliability and validity in bone marrow and stem cell transplant patients
    Deborah B McGuire
    School of Nursing, University of Pennsylvania, 420 Guardian Drive, Philadelphia, PA 19104, USA
    Cancer Invest 20:893-903. 2002
  2. ncbi request reprint Managing pain in mucositis
    Joel B Epstein
    Department of Oral Medicine and Diagnostic Sciences, College of Dentistry, Interdisciplinary Program in Oral Cancer, Chicago Cancer Center, Chicago, IL 60612, USA
    Semin Oncol Nurs 20:30-7. 2004
  3. ncbi request reprint Oral graft-versus-host disease
    Mark M Schubert
    Oral Medicine Service, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Seattle, WA 98109, USA
    Dent Clin North Am 52:79-109, viii-ix. 2008
  4. ncbi request reprint A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation
    Mark M Schubert
    Department of Oral Medicine, Seattle Cancer Care Alliance, University of Washington, 825 Eastlake Ave E, Seattle, WA 98109, USA
    Support Care Cancer 15:1145-54. 2007
  5. ncbi request reprint A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:495-505. 2005
  6. pmc Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease
    Paul J Martin
    Divisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:922-9. 2012
  7. ncbi request reprint Management of oropharyngeal mucositis pain
    Mark M Schubert
    Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington, USA
    Tex Dent J 127:463-81. 2010
  8. ncbi request reprint Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia
    Kim Robien
    Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 22:1268-75. 2004
  9. ncbi request reprint Management of oral mucositis pain
    Mark M Schubert
    Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington, USA
    Tex Dent J 121:507-18. 2004
  10. ncbi request reprint Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease
    Paul A Carpenter
    Biol Blood Marrow Transplant 12:792-4. 2006

Detail Information

Publications17

  1. ncbi request reprint The 20 item oral mucositis index: reliability and validity in bone marrow and stem cell transplant patients
    Deborah B McGuire
    School of Nursing, University of Pennsylvania, 420 Guardian Drive, Philadelphia, PA 19104, USA
    Cancer Invest 20:893-903. 2002
    ..Provided that clinical examiners have appropriate training and experience, the OMI-20 can be used as a reliable, valid, and quantifiable measure of mucositis in clinical research...
  2. ncbi request reprint Managing pain in mucositis
    Joel B Epstein
    Department of Oral Medicine and Diagnostic Sciences, College of Dentistry, Interdisciplinary Program in Oral Cancer, Chicago Cancer Center, Chicago, IL 60612, USA
    Semin Oncol Nurs 20:30-7. 2004
    ..To discuss pharmacologic and nonpharmacologic approaches available to manage pain...
  3. ncbi request reprint Oral graft-versus-host disease
    Mark M Schubert
    Oral Medicine Service, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Seattle, WA 98109, USA
    Dent Clin North Am 52:79-109, viii-ix. 2008
    ..Topical and local management of symptomatic oral GVHD can reduce oral symptoms that can interfere with oral function and quality of life, and can reduce the need for more intensive immunosuppressive systemic therapies...
  4. ncbi request reprint A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation
    Mark M Schubert
    Department of Oral Medicine, Seattle Cancer Care Alliance, University of Washington, 825 Eastlake Ave E, Seattle, WA 98109, USA
    Support Care Cancer 15:1145-54. 2007
    ....
  5. ncbi request reprint A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:495-505. 2005
    ..Although a significant improvement in the prevention of GVHD was not suggested, compared with CSP and MTX, MMF in combination with CSP could be considered in cases in which MTX is contraindicated...
  6. pmc Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease
    Paul J Martin
    Divisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:922-9. 2012
    ..Inconsistent adherence related to mucositis during recovery after myeloablative conditioning may have obscured a beneficial therapeutic effect in the current study...
  7. ncbi request reprint Management of oropharyngeal mucositis pain
    Mark M Schubert
    Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington, USA
    Tex Dent J 127:463-81. 2010
    ....
  8. ncbi request reprint Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia
    Kim Robien
    Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 22:1268-75. 2004
    ..The objective of this study was to evaluate factors predicting oral mucositis severity among 133 patients undergoing allogeneic HCT for chronic myelogenous leukemia...
  9. ncbi request reprint Management of oral mucositis pain
    Mark M Schubert
    Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington, USA
    Tex Dent J 121:507-18. 2004
    ..By utilizing the principles of a individualized, tiered approach to pain management, that address the multidimensional components of a patient's pain, maximum comfort can be consistently provided while reducing the risk for side-effects...
  10. ncbi request reprint Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease
    Paul A Carpenter
    Biol Blood Marrow Transplant 12:792-4. 2006
  11. ncbi request reprint Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice
    Douglas E Peterson
    Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, 06030 1605, USA
    Support Care Cancer 14:499-504. 2006
    ....
  12. ncbi request reprint Alimentary mucositis: putting the guidelines into practice
    Michael T Brennan
    Carolinas Medical Center, Charlotte, NC, USA
    Support Care Cancer 14:573-9. 2006
    ..The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology completed an evidence-based review of the literature for the management of alimentary mucositis...
  13. ncbi request reprint Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls
    Dorothy M Keefe
    Department of Medical Oncology, Royal Adelaide Hospital Cancer Centre, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, 5000, Australia
    Support Care Cancer 14:492-8. 2006
    ....
  14. ncbi request reprint Amifostine in the management of radiation-induced and chemo-induced mucositis
    Rene Jean Bensadoun
    Department of Radiation Oncology, Centre Antoine Lacassagne, 33 av de Valombrose, 06189, Nice, Cedex 2, France
    Support Care Cancer 14:566-72. 2006
    ..The goal of this literature review is to update previously published guidelines for the management of mucositis...
  15. ncbi request reprint Anti-inflammatory agents in the management of alimentary mucositis
    Rajesh V Lalla
    Department of Oral Health and Diagnostic Sciences MC1605, University of Connecticut Health Center, 263, Farmington Avenue, Farmington, 06030 1605, USA
    Support Care Cancer 14:558-65. 2006
    ..Alimentary mucositis is a significant complication of cancer therapy, with important clinical and economic implications...
  16. ncbi request reprint Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working
    Daniel Couriel
    University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Biol Blood Marrow Transplant 12:375-96. 2006
    ..Optimal care of patients with chronic GVHD often requires a multidisciplinary approach...
  17. ncbi request reprint Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management
    Joel B Epstein
    Department of Oral Medicine and Diagnostic Sciences, College of Dentistry, University of Illinois, Program in Oral Cancer, College of Medicine, Chicago Cancer Center, Chicago, Illinois, USA
    Oncology (Williston Park) 17:1767-79; discussion 1779-82, 1791-2. 2003
    ..Continuing research related to the pathogenesis and management of mucositis will undoubtedly lead to the development of potential interventions and improved patient care...